Nasal glucagon is seen as a game-changing delivery method to replace the multistep system of mixing powder and liquid with a simple, 1-step spray. The FDA Wednesday approved Eli Lilly & Co.’s nasal ...

The Food and Drug Administration (FDA) has approved Baqsimi (glucagon; Eli Lilly) nasal powder for the treatment of severe hypoglycemia in patients with diabetes aged 4 years and older. The Food and ...

Each Baqsimi device includes 1 dose of glucagon and cannot be refused. The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of ...

Heading back to school — whether it’s the first day of kindergarten or last year of college — is an exciting time. But for parents of children ages four years and above living with diabetes, the ...

School personnel should soon be allowed to administer a new nasal spray used to treat severe hypoglycemia. In 2019, the Food and Drug Administration approved the use of Baqsimi nasal powder, the first ...

Baqsimi (glucagon) is a prescription drug that’s used to help treat emergency episodes of low blood sugar in adults and some children with diabetes. Baqsimi comes as a powder for nasal inhalation.

(RTTNews) - Pharma major Eli Lilly and Company (LLY) said on Monday that it has inked a deal with Amphastar Pharmaceuticals, Inc. (AMPH), to divest BAQSIMI, the dry nasal spray to treat very low blood ...

The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that can be administered without an ...

The US Food and Drug Administration (FDA) has approved the first nasally administered glucagon product (Baqsimi, Eli Lilly and Co) for the treatment of severe hypoglycemia for patients aged 4 years or ...

In June 2023, AMPH completed the acquisition of Baqsimi from Lilly for an upfront payment of $500 million and is required to pay $125 million on the completion of one year from the day of the closing ...

Eli Lilly announced Monday morning that it is divesting Baqsimi, its low blood sugar rescue treatment, to Amphastar Pharmaceuticals for $500 million. The boards of directors at both companies have ...